Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—We assessed the lifetime risk of cardiovascular disease (CVD) among individuals with and without obesity and diabetes. RESEARCH DESIGN AND METHODS—Participants were drawn from the original and offspring cohorts of the Framingham Heart Study. Lifetime (30-year) risk of CVD was assessed using a modified Kaplan-Meier approach adjusting for the competing risk of death, beginning from age 50 years. RESULTS—Over 30 years, the lifetime risk of CVD among women with diabetes was 54.8% among normal-weight women and 78.8% among obese women. Among normal-weight men with diabetes, the lifetime risk of CVD was 78.6%, whereas it was 86.9% among obese men. CONCLUSIONS—The lifetime risk of CVD among individuals with diabetes is high, and this relationship is further accentuated with increasing adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individuals with type 2 diabetes have a lifetime risk of CAD that includes 67% of women and 78% of men and is exacerbated by obesity ( 22 , 80 , 165 ).”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [80]
Experimental — accuracy not yet measuredIn the citing paper
“In the Framingham Heart Study, Fox [7] reported that, along with the increasing T2DM prevalence, the attributable risk of CVD due to T2DM increased from 5.4% in the period 1952–1974 to 8.7% in the period 1975 and 1998.”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lifetime risk for diabetes mellitus in the United States
Narayan, K. M. V. (2003) · JAMA · doi:10.1001/jama.290.14.1884 · Cited by 1,515
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
Lloyd-Jones, D. M., Leip, E. P., Larson, M. G., D’Agostino, R. B., Beiser, A., Wilson, P. W. F., Wolf, P. A., & Levy, D. (2006) · Circulation · doi:10.1161/circulationaha.105.548206 · Cited by 1,298 · cited 1×
“The lifetime risk of coronary heart disease is 42% among men and 25% among women (2) and is higher among individuals with diabetes (3).”
Self-citationLifetime risk of developing coronary heart disease
Lloyd-Jones, D. M., Larson, M. G., Beiser, A., & Levy, D. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10279-9 · Cited by 929
Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study
Fox, C. S., Coady, S., Sorlie, P. D., D’Agostino, R. B., Pencina, M. J., Vasan, R. S., Meigs, J. B., Levy, D., & Savage, P. J. (2007) · Circulation · doi:10.1161/circulationaha.106.658948 · Cited by 656
Self-citationImpact of Recent Increase in Incidence on Future Diabetes Burden
Narayan, K. M. V., Boyle, J. P., Geiss, L. S., Saaddine, J. B., & Thompson, T. J. (2006) · Diabetes Care · doi:10.2337/dc06-1136 · Cited by 602
Effect of BMI on Lifetime Risk for Diabetes in the U.S.
Narayan, K. M. V., Boyle, J. P., Thompson, T. J., Gregg, E. W., & Williamson, D. F. (2007) · Diabetes Care · doi:10.2337/dc06-2544 · Cited by 510
Gaynor, J. J., Feuer, E. J., Tan, C. C., Wu, D. H., Little, C. R., Straus, D. J., Clarkson, B. D., & Brennan, M. F. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10476289 · Cited by 483 · cited 2×
“For computing the 10, 20, and 30-year risks, we used the Practical Incidence Estimators (PIE) macro approach developed by Beiser et al (4) based on a method proposed by Gaynor et al (5) as previously described (6).”
Beiser, A., D'Agostino, R. B., Seshadri, S., Sullivan, L. M., & Wolf, P. A. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000615/30)19:11/12<1495::aid-sim441>3.0.co;2-e · Cited by 186
Self-citationEstimated Risks for Developing Obesity in the Framingham Heart Study
Vasan, R. S., Pencina, M. J., Cobain, M., Freiberg, M. S., & D'Agostino, R. B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-7-200510040-00005 · Cited by 158
Self-citationTemporal Trends in BMI Among Adults With Diabetes
Leibson, C. L., Williamson, D. F., Melton, L. J., Palumbo, P. J., Smith, S. A., Ransom, J. E., Schilling, P. L., & Narayan, K. M. V. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1584 · Cited by 112 · cited 1×
“The prevalence of obesity among individuals with diabetes continues to rise (1).”
Cited by
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Self-citationHeart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
Self-citationHeart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,215
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationWRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191259 · Cited by 3,908
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
“Obesity as a risk factor for CVD Obesity has long been established as an independent risk factor for CVD [7, 52], and is associated with CAD [53, 54], atherosclerosis [51], and cardiac death [55, 56].”
BackgroundColberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan-Taber, L., Albright, A. L., & Braun, B. (2010) · Diabetes Care · doi:10.2337/dc10-9990 · Cited by 1,955
“Individuals with type 2 diabetes have a lifetime risk of CAD that includes 67% of women and 78% of men and is exacerbated by obesity (22,80,165).”
Pi-Sunyer, X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2074 · Cited by 1,025
Pi-Sunyer, F. X. (2002) · Obesity Surgery · doi:10.1007/bf03342140 · Cited by 827
Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001191 · Cited by 797
Self-citation(2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181eeb61c · Cited by 567
“Individuals with T2DM have a lifetime risk of CAD that includes 67% of women and 78% of men and is exacerbated by obesity (22,80,165).”
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1096 · Cited by 468
“The lifetime risk of cardiovascular disease in patients with diabetes is 67–78% (1).”
BackgroundV Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose
Xavier, H. T., Izar, M. C., Faria Neto, J. R., Assad, M. H., Rocha, V. Z., Sposito, A. C., Fonseca, F. A., Santos, J. E. D., Santos, R. D., Bertolami, M. C., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s010 · Cited by 454
Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety
Shaito, A., Thuan, D. T. B., Phu, H. T., Nguyen, T. H. D., Hasan, H., Halabi, S., Abdelhady, S., Nasrallah, G. K., Eid, A. H., & Pintus, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00422 · Cited by 437
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400
“10 years 40 (19) 51 (24) 51 (24) 142 (22) 17 (25)”
BackgroundLeggio, M., Lombardi, M., Caldarone, E., Severi, P., D'Emidio, S., Armeni, M., Bravi, V., Bendini, M. G., & Mazza, A. (2017) · Hypertension Research · doi:10.1038/hr.2017.75 · Cited by 309
The impact of diabetes on cognitive impairment and its progression to dementia
Dove, A., Shang, Y., Xu, W., Grande, G., Laukka, E. J., Fratiglioni, L., & Marseglia, A. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12482 · Cited by 252
Grover, S. A., Kaouache, M., Rempel, P., Joseph, L., Dawes, M., Lau, D. C. W., & Lowensteyn, I. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70229-3 · Cited by 223
Caloric restriction: powerful protection for the aging heart and vasculature
Weiss, E. P., & Fontana, L. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00685.2011 · Cited by 198
“While improvements in glycemic control have been hypothesized to contribute to the antiaging effect of CR (30), they would also be expected to protect against atherosclerosis and CVD, as hyperglycemia, insulin resistance, and diabetes are associated with atherosclerosis and CVD risk (13, 69, 76, 90, 215).”
BackgroundI Diretriz Brasileira de Prevenção Cardiovascular
Simão, A., Precoma, D., Andrade, J., Correa Filho, H., Saraiva, J., Oliveira, G., Murro, A., Campos, A., Alessi, A., Avezum Junior, A., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s012 · Cited by 178
Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial
de Courten, B. V., Jakubová, M., de Courten, M., Kukurová, I. J., Vallova, S., Krumpolec, P., Valkovič, L., Kurdiová, T., Garzon, D., Barbaresi, S., et al. (2016) · Obesity · doi:10.1002/oby.21434 · Cited by 156
“Obesity markedly increases the risk of developing type 2 diabetes, and 80% of those with both obesity and type 2 diabetes develop cardiovascular diseases (2).”
BackgroundSong, S. H., & Hardisty, C. A. (2009) · QJM · doi:10.1093/qjmed/hcp121 · Cited by 147
“Obesity is known to accentuate the lifetime risk for CVD in diabetes.(10) In our study, vast majority (>90%) of early onset subjects with short diabetes duration were either overweight or obese.”
BackgroundEffect of diabetes mellitus on sleep quality
Surani, S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.868 · Cited by 147
Circulating Endothelial Microparticles in Diabetes Mellitus
Tramontano, A. F., Lyubarova, R., Tsiakos, J., Palaia, T. A., DeLeon, J. R., & Ragolia, L. (2010) · Mediators of Inflammation · doi:10.1155/2010/250476 · Cited by 152
“DM is a major risk factor for cardiovascular morbidity and mortality, and the proportion of cardiovascular disease attributable to DM has increased over the past 50 years [7].”
BackgroundGanoderma lucidum : a comprehensive review of phytochemistry, efficacy, safety and clinical study
Wu, S., Zhang, S., Peng, B., Tan, D., Wu, M., Wei, J., Wang, Y., & Luo, H. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250051 · Cited by 159
Targeting white, brown and perivascular adipose tissue in atherosclerosis development
van Dam, A. D., Boon, M. R., Berbée, J. F. P., Rensen, P. C. N., & van Harmelen, V. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.051 · Cited by 113
“More insight into the relation between adipose tissue types and atherosclerosis will provide novel targets to treat (obese) individuals with high risk of CVD.”
BackgroundInfluentialNishimura, R., Tanaka, Y., Koiwai, K., Inoue, K., Hach, T., Salsali, A., Lund, S. S., & Broedl, U. C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0169-9 · Cited by 106
D’Andrea, E., Hey, S. P., Ramirez, C. L., & Kesselheim, A. S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2224 · Cited by 111
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 92
“Increasing adiposity is known to independently contribute to increased cardiovascular disease risk in diabetes.(29) Weight loss also contributes, in part, to the blood pressure reduction and lipid changes observed with SGLT2 inhibitor therapy.”
BackgroundImpact of weight gain on outcomes in type 2 diabetes
Ross, S. A., Dzida, G., Vora, J., Khunti, K., Kaiser, M., & Ligthelm, R. J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585396 · Cited by 91
Causey, M. W., Johnson, E. K., Miller, S., Martin, M. J., Maykel, J. A., & Steele, S. R. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e3182342ccb · Cited by 91
Dyslipidemia in diabetes mellitus and cardiovascular disease
Warraich, H. J., & Rana, J. S. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000120 · Cited by 103
Obesity stigma: A newly recognized barrier to comprehensive and effective type 2 diabetes management
Teixeira, M. E., & Budd, G. M. (2010) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2010.00551.x · Cited by 101
“Obesity is known to accelerate the cardiovascular and diabetic processes that can result in increased morbidity and mortality (Fox et al., 2008).”
BackgroundPi-Sunyer, F. X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2056 · Cited by 86
“9% in men.(8) A recent Swedish National Diabetes Register study showed that both overweight and obesity independently increase the risk of CVD in patients with type 2 diabetes.”
BackgroundKramer, H., Cao, G., Dugas, L. R., Luke, A. H., Cooper, R., & Durazo-Arvizú, R. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2009.10.001 · Cited by 81
Long-term Absolute Risk for Cardiovascular Disease Stratified by Fasting Glucose Level
Bancks, M. P., Ning, H., Allen, N. B., Bertoni, A. G., Carnethon, M. R., Correa, A., Echouffo-Tcheugui, J. B., Lange, L. A., Lloyd-Jones, D. M., & Wilkins, J. T. (2019) · Diabetes Care · doi:10.2337/dc18-1773 · Cited by 80
“Previous long-term absolute risk estimates for incident CVD among individuals with diabetes at midlife range from 49% to 67% for women and 62% to 78% for men (2,3).”
BackgroundResultInfluentialEpidemiology of ischaemic heart disease in sub-Saharan Africa : review article
Onen, C. L. (2013) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2012-071 · Cited by 85
“Although the results of the INTERHEART study have been challenged on account of it being a case–control study rather than a prospective study, the major contributing individual risk factors for acute myocardial infarction are generally consistent across the globe and reminiscent of the conclusions of the original Fram…”
ResultWang, C. C. L., & Reusch, J. E. B. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.036 · Cited by 82
Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 83
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 72
Nanna, M. G., Kolkailah, A. A., Page, C., Peterson, E. D., & Navar, A. M. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.3839 · Cited by 66
Batchelor, R., Kumar, R., Gilmartin‐Thomas, J., Hopper, I., Kemp, W. W., & Liew, D. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14955 · Cited by 70
The Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock
Kengne, A. P., Turnbull, F., & MacMahon, S. W. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.02.010 · Cited by 76
Implication of dietary phenolic acids on inflammation in cardiovascular disease
Ali, S. S., Ahmad, W. A. N. W., Budin, S. B., & Zainalabidin, S. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.02.49 · Cited by 63
Marini, S., Trifoglio, E., Barbarini, N., Sambo, F., Di Camillo, B., Malovini, A., Manfrini, M., Cobelli, C., & Bellazzi, R. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.08.021 · Cited by 61
Barnett, A. H., Patel, S., Harper, R., Toorawa, R., Thiemann, S., von Eynatten, M., & Woerle, H. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12011 · Cited by 71
“Medication-induced weight gain is particularly undesirable in patients with T2DM, as >85% are already overweight or obese [38,39]; additional weight gain could further elevate their high risk for cardiovascular disease [40,41] as well as reducing quality of life and adherence to treatment [42–44].”
BackgroundJiang, K., Chen, B., Lou, D., Zhang, M., Shi, Y., Dai, W., Shen, J., Zhou, B., & Hu, J. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04190-y · Cited by 67
Matsha, T. E., Hassan, M. S., Kidd, M., & Erasmus, R. T. (2012) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2010-087 · Cited by 73
“It is well documented that individuals with type 2 DM have increased CVD risk compared to those without diabetes, and the 30-year risk among subjects with diabetes has been shown to proportionally increase with BMI.26,27 However, no significant differences were observed between obese and normal-weight diabetics in thi…”
BackgroundCardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59
“Increasing adiposity is known to independently contribute to increased cardiovascular disease risk in diabetes.(29) Weight loss also contributes, in part, to the blood pressure reduction and lipid changes observed with SGLT2 inhibitor therapy.”
BackgroundLin, F., Tseng, W.-K., Yin, W., Yeh, H., Chen, J., & Wu, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-08741-0 · Cited by 64
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
Kurukulasuriya, L. R., & Sowers, J. R. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-45 · Cited by 63
The Perception of Health Risks
Renner, B., & Schupp, H. T. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780195342819.013.0026 · Cited by 64
Nelson, A. J., Peterson, E. D., & Pagidipati, N. J. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.001 · Cited by 52
Moberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G., Casalini, E. D., Hutchins, G. D., Green, M. A., Ng, Y., Considine, R. V., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0365-x · Cited by 51
“Type 2 diabetes (T2DM) and pre-diabetic states of obesity and insulin resistance are associated with augmented cardiovascular risk [10, 19, 37], through mechanisms involving abnormal fuel delivery and utilization, and vascular dysfunction [45].”
BackgroundLipid control in patients with diabetes mellitus
Betteridge, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.23 · Cited by 58
“For example, obesity has a substantial impact on lifetime CVD risk”
BackgroundRahman, A., Hitomi, H., & Nishiyama, A. (2017) · Hypertension Research · doi:10.1038/hr.2016.193 · Cited by 50
Vascular Protection in People with Diabetes
Stone, J. A., Fitchett, D., Grover, S. A., Lewanczuk, R. Z., & Lin, P. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.030 · Cited by 49
Booth, H., Prevost, A. T., & Gulliford, M. C. (2015) · Journal of Human Hypertension · doi:10.1038/jhh.2015.23 · Cited by 43
Barnett, A. H. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2698 · Cited by 44
Paynter, N. P. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.351 · Cited by 38
“Other timescales of risk may also be important in evaluating treatment decisions and were not explored in this analysis, including lifetime risk of CVD, which has been shown to be higher for the diabetic population.(24) Lifetime risk might also provide additional comparability across populations.”
Self-citationAssociation of Cardiometabolic Disease With Cancer in the Community
Liu, E. E., Suthahar, N., Paniagua, S. M., Wang, D., Lau, E. S., Li, S. X., Jovani, M., Takvorian, K. S., Kreger, B. E., Benjamin, E. J., et al. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.01.095 · Cited by 40
Self-citationHeart rate management in coronary artery disease: the CLARIFY registry
Steg, P. G. (2009) · European Heart Journal Supplements · doi:10.1093/eurheartj/sup017 · Cited by 40
Zhang, R., Mamza, J. B., Morris, T., Godfrey, G., Asselbergs, F. W., Denaxas, S., Hemingway, H., & Banerjee, A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02234-2 · Cited by 45
Role for Combination Therapy in Diabetic Dyslipidemia
Warraich, H. J., Wong, N. D., & Rana, J. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0589-5 · Cited by 41
Cardiovascular Health of Retired Field-Based Athletes: A Systematic Review and Meta-analysis
McHugh, C., Hind, K., Davey, D., & Wilson, F. (2019) · Orthopaedic Journal of Sports Medicine · doi:10.1177/2325967119862750 · Cited by 39
Primary and Secondary Prevention of Coronary Heart Disease
Gaziano, J. M., Ridker, P. M., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00049-4 · Cited by 34
Basiri, R., Seidu, B., & Cheskin, L. J. (2023) · Nutrients · doi:10.3390/nu15183929 · Cited by 41
Eastwood, S. V., Mathur, R., Sattar, N. A., Smeeth, L. L., Bhaskaran, K., & Chaturvedi, N. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003672 · Cited by 31
“To assess the population impact of equalising statin prescribing across ethnic groups, we applied 2011 census ethnicity proportions [28] to the estimated UK population of people with type 2 diabetes [29] and assumed a lifetime ASCVD risk of 62% [30], giving 213,900 and 94,116 expected ASCVD events in people of South A…”
MethodTönis, K. J. M., Kraiss, J. T., Linssen, G. C. M., & Bohlmeijer, E. T. (2023) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2023.111328 · Cited by 39
Health Utilities of Type 2 Diabetes-Related Complications: A Cross-Sectional Study in Sweden
Kiadaliri, A., Gerdtham, U., Eliasson, B., Guðbjörnsdóttir, S., Svensson, A., & Carlsson, K. S. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110504939 · Cited by 33
“The Framingham Heart Study revealed that the 30-year risk of developing cardiovascular disease was significantly higher among men and women with diabetes compared to those without diabetes [6].”
Jhund, P. S., McMurray, J. J. V., Chaturvedi, N., Brunel, P., Desai, A. S., Finn, P. V., Haffner, S. M., Solomon, S. D., Weinrauch, L. A., Claggett, B. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv295 · Cited by 32
Complementing Insulin Therapy to Achieve Glycemic Control
Barnett, A. H. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0039-y · Cited by 38
“Insulin therapy is associated with an increased risk of hypoglycemia and weight gain, both of which can increase morbidity and mortality [30–34].”
BackgroundDiamond, D. M., O’Neill, B. J., & Volek, J. S. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000568 · Cited by 34
Hollander, P., Lasko, B., Barnett, A. H., Bengus, M., Kanitra, L., Pi‐Sunyer, F. X., & Balena, R. (2013) · Obesity · doi:10.1002/oby.20042 · Cited by 30
“Furthermore, the majority of newly diagnosed cases of diabetes can be directly attributed to obesity (3), and patients with both obesity and type 2 diabetes are at high risk for cardiovascular disease since obesity exacerbates pre-existing cardiometabolic abnormalities (4-6).”
BackgroundBeyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2054 · Cited by 37
“Recent fi ndings from the Framingham Heart Study and the Swedish National Diabetes Register (SNDR) strengthen the connection between the role of overweight/obesity and type 2 diabetes in the metabolic syndrome, and increased CV risk.(10,11) Individuals with and without diabetes from the original and offspring cohorts…”
MethodJones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 36
Goldberg, R. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.011 · Cited by 34
The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
Abohelwa, M., Kopel, J. J., Shurmur, S. W., Ansari, M. M., Awasthi, S., & Awasthi, S. (2023) · Journal of Vascular Diseases · doi:10.3390/jvd2010010 · Cited by 62
“Furthermore, DM at age 50 increased this risk to 67% in men and 57% for women, respectively [47,49].”
BackgroundInfluentialZhong, X., Lai, D., Ye, Y., Yang, X., Yu, B., & Huang, Y. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2010-8 · Cited by 34
“Overweight/obesity is a significant CV risk factor and increases insulin resistance [27, 28].”
BackgroundCardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes
Ovalle, F. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.006 · Cited by 28
Exposure to phthalates and cardiovascular diseases in Chinese with type 2 diabetes
Zhang, H., Chen, J., Chen, C., Wan, H., Chen, Y., Wang, Y., Zhang, W., Chen, B., Wang, N., & Lu, Y. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-14807-4 · Cited by 29
Diabetes, Cardiovascular Risk and Nephropathy
Hahr, A. J., & Molitch, M. E. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.04.006 · Cited by 29
Cardiovascular Risk Assessment in the 21st Century
Gaziano, J. M., & Wilson, P. W. F. (2012) · JAMA · doi:10.1001/2012.jama.10456 · Cited by 28
Self-citationPrescribing Exercise for Individuals with Type 2 Diabetes: Recommendations and Precautions
Colberg, S. R., & Sigal, R. J. (2011) · The Physician and Sportsmedicine · doi:10.3810/psm.2011.05.1909 · Cited by 28
The Best Obesity Indices to Discriminate Type 2 Diabetes Mellitus
Motamed, N., Rabiee, B., Keyvani, H., Hemasi, G. R., Khonsari, M. R., Saeedian, F. S., Maadi, M., & Zamani, F. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0133 · Cited by 23
Nichols, G. A., Vupputuri, S. X., & Rosales, A. G. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.05.047 · Cited by 23
Management of Lipid Abnormalities in Patients with Diabetes
Sillars, A., & Sattar, N. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1246-1 · Cited by 24
Digital Health in Diabetes and Cardiovascular Disease
Avoke, D., Elshafeey, A., Weinstein, R. A., Kim, C. H., & Martin, S. S. (2024) · Endocrine Research · doi:10.1080/07435800.2024.2341146 · Cited by 30
“Obesity is a well-established independent risk factor for cardiovascular disease and is associated with higher risk of coronary artery disease, 32–34 atherosclerosis, 35 and fatal cardiac events.”
BackgroundNew Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals
Wysham, C. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2142 · Cited by 23
“that the lifetime risk of CVD among patients with diabetes is further increased by excess weight, irrespective of baseline weight.(3) The risk of obese men and women developing CVD over 30 years is 67% and 47%, respectively.”
BackgroundWarraich, H. J., & Rana, J. S. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1068-6 · Cited by 24
Metabolic health, obesity and 9-year incidence of peripheral arterial disease: The D.E.S.I.R. study
Skilton, M. R., Chin-Dusting, J. P. F., Dart, A. M., Brazionis, L., Lantieri, O., O’Dea, K., & Balkau, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.032 · Cited by 23
Shad, A. N., Akhlaghipour, I., Baghan, A. B., Askari, V. R., & Rahimi, V. B. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400240 · Cited by 21
Andersson, C., & Vasan, R. S. (2014) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.113.000470 · Cited by 21
Self-citationCardiorespiratory fitness and mortality in diabetic men with and without cardiovascular disease
McAuley, P. A., MYERS, J. N., Emerson, B. T., Oliveira, R. B., Blue, C. L., Pittsley, J. L., & Froelicher, V. F. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.05.012 · Cited by 22
“The lifetime risk of cardiovascular disease (CVD) is higher for individuals with diabetes [1,2].”
Background
Metadata
- Authors
- Fox, C. S., Pencina, M. J., Wilson, P. W. F., Paynter, N. P., Vasan, R. S., & D’Agostino, R. B.
- Affiliations
- Brigham and Women's Hospital (US)
- Boston University (US)
- Emory University (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-08-01
- Volume
- 31
- Issue
- 8
- Pages
- 1582-1584
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2494632
- OpenAlex
- W2154705833
- Cited by
- 247
- References
- 10
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 17 · 2023: 13 · 2022: 22 · 2021: 17 · 2020: 10 · 2019: 10 · 2018: 9 · 2017: 14 · 2016: 10 · 2015: 11 · 2014: 13 · 2013: 17 · 2012: 18
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- OpenBU (Boston University) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (n01hc25195-41-0-1)
- National Heart, Lung, and Blood Institute (N01‐HC25195, K24HL004334, N01-HC-025195)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- diabetes mellitus, obesity, adiposity, sex differences, competing risk of death, Framingham Heart Study, women
- MeSH terms
- Aged, Aged, 80 and over, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Obesity, Time Factors, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.